Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

More documents

Recommendations

Info

64Annual Report on Lymphatic Filariasis 2003Chapter 3 Programme implementationFigure 3.69 Outcomes and planning 2000-2007No. of IUs1086420% of at-risk population covered100No. IUs502003Planned pop. coverage75252004Figure 3.71 Geographical coverageNO DATAAVAILABLE0.80.60.40.20.0Pop. reported to haveingested drugsmillion peopleThe LF elimination programme is implemented by theMinistry of Health of Guyana with the technical cooperationof PAHO/WHO’s country and regional officesand with the close collaboration of a wide range of partnersincluding CDC, the Emory LF Support Center, theLiverpool LF Support Centre and UNICEF. The Bill andMelinda Gates Foundation is currently the principalfinancial partner of the initiative.Figure 3.70 LF at-risk populationPopulation in millions2.01.51.00.50.0100Total pop.0.71 MAt-risk pop.0.64 MFigure 3.72 MDA reported coverage020022003Figure 3.73 IUs with reported coverage >65%%908070NO DATAAVAILABLE10060805020022003%6040NO DATAAVAILABLE20Figure 3.74 Updated mapping statusTotal: 10 IUs020022003— 1 IU 9 IUsUncertain Non-endemic Endemic
HAITI65Endemicity statusEndemicNon-endemicUncertainAnnual Report on Lymphatic Filariasis 2003LF is a major health problem for Haiti’s population of morethan 8 million. There is no sentinel site data of LF clinicalmanifestations but Dr Y. Michelet, in his medical dissertationin 1981, reported a hydrocele and lymphoedemaprevalence of 32% and 7.2%, respectively, in Leogane city.The administrative division designated as an IU in thecountry is the commune. LF mapping was completedin 2001: 119 communes (IUs) out of 133 are consideredendemic for LF with an at-risk population considered tobe 8 million. The prevalence evaluated by ICT was 3.9%(range: 1.3% to 13.4%)The first round of MDA started in 2001 with DEC and albendazoleco-administration and covered the Leogane IU. Thesecond MDA round in 2002 covered nine IUs. Three IUs— Arcahaie, Tabarre and Gressier, with a target populationof around 100 000 — were targeted for DEC-salt strategyin 2003. In the third round of MDA in 2003, 757 976people were targeted with a reported coverage of 77% forsix communes where the MDA was done (because of someoperational difficulties, not all the communes targeted inthe planning operational plan were effectively covered).Mapping with ICT cards demonstrated an LF prevalenceof 7% to 28% for new districts that started MDA in 2003,and the mf prevalence found in sentinel sites ranged from1.8% to 28.6%. Between 2001 and 2003, 2541 drug distributorswere trained and 30 people participated in trainingin disability prevention and control.The LF elimination programme is implemented by theministry of health assisted by a wide range of partners.WHO provides financial and technical support;the University of Notre Dame, USA, provides supportfor research and CDC provides technical assistanceand funding. Interchurch Medical Assistance, UNICEF,Hôpital Saint Croix and Hôpital Sacré Coeur in Milot areChapter 3 Programme implementationTable 3.14 Goal: to eliminate LF from Haiti as a public health problem by 2020Objectives• To interrupt transmission of LF• To prevent LF-associated disabilityStrategies• Expand MDA campaigns (DEC plus albendazole)• MDA (DEC-fortified salt) in 3 IUs (100 000 people)• Disability management clinics• Increase the number of community-based support groups• Continue operational research to optimize patient care and monitoringand evaluation techniques
Page 1 and 2:
For further information about lymph
Page 3:
WHO/CDS/CPE/CEE/2005.52GlobalProgra
Page 7 and 8:
3Report of the Technical Advisory G
Page 9 and 10:
P R O G R A M M E H I G H L I G H T
Page 11:
I N T R O D U C T I O N7This Annual
Page 14 and 15:
10Annual Report on Lymphatic Filari
Page 16 and 17:
12Annual Report on Lymphatic Filari
Page 18 and 19: 14Annual Report on Lymphatic Filari
Page 42 and 43: 38Figure 3.2 Outcomes and planning
Page 59 and 60: UNITED REPUBLIC OF TANZANIA55Endemi
Page 61 and 62: ZANZIBAR, UNITED REPUBLIC OF TANZAN
Page 63: 59AMERICAN PROGRAMME REVIEWGROUPAt
Page 86 and 87: 82Figure 3.100 Outcomes and plannin
Page 104 and 105: 100Annual Report on Lymphatic Filar
Page 118 and 119:
114Figure 3.196 Outcomes and planni
Page 120 and 121:
116Annual Report on Lymphatic Filar
Page 122 and 123:
Page 124 and 125:
Page 127:
C H A P T E R 6FURTHER DOCUMENTATIO
Page 130 and 131:
Page 132 and 133:
Page 135 and 136:
ANNUAL REPORT FOR THE NATIONAL PROG
Page 137 and 138:
1332. PROGRAMME RESOURCES2.1 Please
Page 139 and 140:
1353.3 Interruption of transmission
Page 141 and 142:
1373.3.6a Report of MDA coverage by
Page 143 and 144:
1393.3.7 Surveys in sentinel sites
Page 145 and 146:
1413.3.10 Please attach a map of th
Page 147 and 148:
1434. SERIOUS ADVERSE EXPERIENCES (
Page 149 and 150:
A N N E X E SANNEX 3: LIST OF LF-EN
Page 151 and 152:
147RAPLOARPRGSAESEAROTAG-LFTDRUNDPU
Page 153 and 154:
149Drug administration and monitori
show all

Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?